Grufity logoGrufity logo

EQRX

3.20USD-0.26(-7.51%)Market Closed

EQRx, Inc.

Market Summary

USD3.20-0.26Market Closed
-7.51%

EQRX Stock Price

RSI Chart

Valuation

Market Cap

2.4B

Price/Earnings

-18.61

Price/Sales

4.6K

Price/Cashflow

-8.01

MarketCap/EBT

-20.21

Price/Sales

Profitability

EBT Margin

-22937.84%

Return on Equity

-8.82%

Return on Assets

-8.08%

Fundamentals

Revenue

Revenue (TTM)

12.9M

Revenue Y/Y

3.7K%

Revenue Q/Q

100.66%

Earnings

Earnings (TTM)

-221.7M

Earnings Y/Y

-1.4K%

Earnings Q/Q

-3.08%

Price Action

52 Week Range

8.70
(Low)(High)

Last 7 days

-8.8%

Last 30 days

-41.7%

Last 90 days

-38.9%

Financial Health

Current Ratio

28.74

Investor Care

Shares Dilution (1Y)

40.80%

Diluted EPS (TTM)

-0.3

Financials for EQRx

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue47.5%12,9038,7474,592436369
Operating Expenses16.8%349,948299,558255,107196,375135,432
  S&GA Expenses22.5%174,132142,169123,60078,26620,475
  R&D Expenses18.0%213,213180,742154,860118,10982,524
Earnings Before Taxes--100,009.00
Net Income-70.5%-221,651.00-130,014.68-79,272.58-100,009.00-69,435.44
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-4.0%1,5431,6081,6741,729554
  Current Assets-4.0%1,5241,5881,6551,7062
    Cash Equivalents15.5%9988641,6231,6792
  Net PPE18.3%2222-
Liabilities7.2%14313412621574
  Current Liabilities13.4%635557402
Shareholder's Equity-5.1%1,4001,4751,5491,515-
  Retained Earnings-20.2%-505.40-420.30-337.80-358.50-72.17
  Additional Paid-In Capital0.5%1,9071,8971,8861,873-
Shares Outstanding0.5%476474471469-
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-20.5%-364,195.67-302,287.04-213,597.00-183,180.00-608.43
  Share Based Compensation15.7%54,73647,32038,34826,2265,088
Cashflow From Investing133.3%48,692-146,224.00-4,418.00-4,448.00-736,000.00
Cashflow From Financing-37.0%821,7581,303,9251,303,9091,376,488739,389

Risks

What is the probability of a big loss on EQRX?

92%


Probability that EQRx stock will be more than 20% underwater in next one year

92%


Probability that EQRx stock will be more than 30% underwater in next one year.

86%


Probability that EQRx stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EQRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if EQRx was unfortunately bought at previous high price.

Returns

Cumulative Returns on EQRX

Which funds bought or sold EQRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
156,000
1,016,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-
-
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-2,000
-
-%
2022-11-15
JANE STREET GROUP, LLC
REDUCED
-59.38
-178,000
133,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
Alphabet Inc.
UNCHANGED
-
12,364,000
235,386,000
12.02%
2022-11-15
STATE STREET CORP
ADDED
58.76
20,540,000
50,940,000
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-76.51
-2,201,000
726,000
-%
2022-11-15
Laurel Wealth Advisors LLC
SOLD OFF
-100
-2,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%

1–10 of 47

Latest Funds Activity

Are funds buying EQRX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own EQRX

EQRx News

Marketing Sentinel

Let's Get Started On The EQRx Inc. (NASDAQ: EQRX) Stock Forecast..13 hours ago

EQRX Fair Value

Recent SEC filings of EQRx

View All Filings
Date Filed Form Type Document
Nov 29, 2022
SC 13D/A
13D - Major Acquisition
Nov 14, 2022
424B3
Prospectus Filed
Nov 10, 2022
10-Q
Quarterly Report
Nov 10, 2022
8-K
Current Report
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for EQRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2021-12-17
BERNS PAUL L
ACQUIRED
-
-
627,000
-
2021-12-17
Abernethy Amy
SOLD
-
-
-200,000
-
2021-12-17
Horning Sandra
ACQUIRED
-
-
470,250
-
2021-12-17
Conde Jorge
ACQUIRED
-
-
19,192,000
-
2021-12-17
Conde Jorge
ACQUIRED
-
-
11,433,700
-
2021-12-17
Conde Jorge
ACQUIRED
50,000,000
10
5,000,000
-
2021-12-17
Conde Jorge
ACQUIRED
-
-
17,438,500
-
2021-12-17
Nallicheri Melanie
ACQUIRED
-
-
3,851,150
Chief Executive Officer
2021-12-17
Nallicheri Melanie
ACQUIRED
-
-
5,679,250
Chief Executive Officer
2021-12-17
Abernethy Amy
ACQUIRED
-
-
200,000
-

1–10 of 21

Melanie I. Nallicheri
240
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

EQRX Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:    
Research and development$ 56,271$ 23,800$ 156,997$ 61,893
General and administrative34,09516,17698,15039,681
Total operating expenses90,36639,976255,147101,574
Loss from operations(90,366)(39,976)(255,147)(101,574)
Other (expense) income:    
Change in fair value of contingent earn-out liability(2,706) 90,863 
Change in fair value of warrant liabilities(197) 4,934 
Interest income, net8,2094712,482210
Other (expense) income, net(32)39(44)131
Total other income, net5,27486108,235341
Net loss(85,092)(39,890)(146,912)(101,233)
Other comprehensive (loss) gain:    
Foreign currency translation adjustments33 49 
Unrealized holding (losses) gains on short-term investments370 (1,672) 
Comprehensive loss$ (84,689)$ (39,890)$ (148,535)$ (101,233)
Net loss per share - basic (in dollars per share)$ (0.18)$ (0.12)$ (0.31)$ (0.32)
Net loss per share - diluted (in dollars per share)$ (0.18)$ (0.12)$ (0.31)$ (0.32)
Weighted average common shares outstanding - basic (in shares)475,565,990320,644,286473,101,935316,837,967
Weighted average common shares outstanding - diluted (in shares)475,565,990320,644,286473,101,935316,837,967

EQRX Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 998,022$ 1,678,542
Short-term investments501,326 
Prepaid expenses and other current assets24,64227,660
Total current assets1,523,9901,706,202
Property and equipment, net1,7941,985
Restricted cash633633
Right-of-use asset4,3552,672
Other investments4,0004,000
Other non-current assets8,64113,950
Total assets1,543,4131,729,442
Current liabilities:  
Accounts payable14,0637,640
Accrued expenses46,10028,904
Lease liability, current2,4963,102
Total current liabilities62,65939,646
Non-current liabilities:  
Contingent earn-out liability62,178153,041
Warrant liabilities16,18121,115
Lease liability, non-current2,060272
Restricted stock repurchase liability373529
Total liabilities143,451214,603
Commitments and contingencies (note 14)
Stockholders' equity:  
Common Stock, $0.0001 par value; 1,250,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 538,428,182 and 537,632,615 shares issued as of September 30, 2022 and December 31, 2021, respectively; and 476,499,567 and 469,369,433 shares outstanding at September 30, 2022 and December 31, 2021, respectively4949
Additional paid-in capital1,906,9471,873,289
Accumulated other comprehensive (loss) income(1,622)1
Accumulated deficit(505,412)(358,500)
Total stockholders' equity1,399,9621,514,839
Total liabilities and stockholders' equity$ 1,543,413$ 1,729,442